These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 11263170

  • 1. [Recurrent epithelial ovarian cancer].
    Ding X, Lang J, Shen K.
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
    [Abstract] [Full Text] [Related]

  • 2. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW, Wu LY, Yao HW, Hou JL, Li XG, Liu LY.
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [Abstract] [Full Text] [Related]

  • 3. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, Bristow RE.
    Cancer; 2007 Feb 15; 109(4):685-91. PubMed ID: 17219441
    [Abstract] [Full Text] [Related]

  • 4. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, Fujii S.
    J Obstet Gynaecol Res; 2006 Dec 15; 32(6):580-7. PubMed ID: 17100820
    [Abstract] [Full Text] [Related]

  • 5. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S, Aliki T, Petros Z, Ioanna S, Konstantinos V, Vasiliki M, George C.
    Gynecol Oncol; 2009 Aug 15; 114(2):178-82. PubMed ID: 19450872
    [Abstract] [Full Text] [Related]

  • 6. [Treatment and prognostic factors of epithelial ovarian cancer].
    Wei L, Qian H, Li W.
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug 15; 32(8):476-9. PubMed ID: 9639741
    [Abstract] [Full Text] [Related]

  • 7. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD, Zhang Q, Zhang Y.
    Ai Zheng; 2005 Aug 15; 24(8):1002-5. PubMed ID: 16086882
    [Abstract] [Full Text] [Related]

  • 8. [Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer].
    Plaisant N, Quenet F, Fabbro M, Gourgou S, Gutowski M, Saint-Aubert B, Rouanet P.
    Gynecol Obstet Fertil; 2004 May 15; 32(5):391-7. PubMed ID: 15177208
    [Abstract] [Full Text] [Related]

  • 9. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
    Zang RY, Zhang ZY, Li ZT, Cai SM, Tang MQ, Chen J, Liu Q.
    Eur J Surg Oncol; 2000 Dec 15; 26(8):798-804. PubMed ID: 11087649
    [Abstract] [Full Text] [Related]

  • 10. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A, Sevelda P.
    Acta Obstet Gynecol Scand; 2001 May 15; 80(5):432-6. PubMed ID: 11328220
    [Abstract] [Full Text] [Related]

  • 11. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY.
    Eur J Surg Oncol; 2009 Oct 15; 35(10):1105-8. PubMed ID: 19443175
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of second cytoreductive surgery in the treatment of epithelial ovarian cancer.
    Sun T, Feng Y.
    Chin Med J (Engl); 1998 Mar 15; 111(3):272-4. PubMed ID: 10374433
    [Abstract] [Full Text] [Related]

  • 13. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C, Gallo A, Carbone A.
    Gynecol Oncol; 2001 Dec 15; 83(3):504-12. PubMed ID: 11733963
    [Abstract] [Full Text] [Related]

  • 14. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ, Liang LZ, Zeng ZY, Liu JH, Yuan SH, Wei M.
    Ai Zheng; 2005 Jun 15; 24(6):751-4. PubMed ID: 15946495
    [Abstract] [Full Text] [Related]

  • 15. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF, Li MD, Liu FY, Liu JH, Li JD.
    Ai Zheng; 2003 Nov 15; 22(11):1193-6. PubMed ID: 14613651
    [Abstract] [Full Text] [Related]

  • 16. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY, Zhang R, Huang MN, Li N, Wang GX, Liu LY.
    Ai Zheng; 2003 Apr 15; 22(4):424-7. PubMed ID: 12704005
    [Abstract] [Full Text] [Related]

  • 17. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR.
    Cancer; 2006 May 01; 106(9):1933-9. PubMed ID: 16572412
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF, Liu FY, Chen FJ, Feng YL.
    Ai Zheng; 2007 Apr 01; 26(4):431-4. PubMed ID: 17430668
    [Abstract] [Full Text] [Related]

  • 19. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
    Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM.
    Eur J Surg Oncol; 2009 Nov 01; 35(11):1186-91. PubMed ID: 19356887
    [Abstract] [Full Text] [Related]

  • 20. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, Gynecologic Oncology Group.
    J Clin Oncol; 2008 Jan 01; 26(1):83-9. PubMed ID: 18025437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.